Literature DB >> 26747694

Role of the FDA in Affordability of Off-Patent Pharmaceuticals.

Jeremy A Greene1, Gerard Anderson2, Joshua M Sharfstein2.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26747694     DOI： 10.1001/jama.2015.18720

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  6 in total

1.  The case for an essential medicines list for Canada.

Authors:  Gina Eom; Paul Grootendorst; Jacalyn Duffin
Journal:  CMAJ       Date:  2016-06-13       Impact factor: 8.262

2.  Trends in Pricing and Generic Competition Within the Oral Antibiotic Drug Market in the United States.

Authors:  Jonathan D Alpern; Lei Zhang; William M Stauffer; Aaron S Kesselheim
Journal:  Clin Infect Dis       Date:  2017-11-13       Impact factor: 9.079

3.  Value-based drug pricing in the Biden era: Opportunities and prospects.

Authors:  Peter J Neumann; Daniel A Ollendorf; Joshua T Cohen
Journal:  Health Serv Res       Date:  2021-06-03       Impact factor: 3.734

4.  Merger mania: mergers and acquisitions in the generic drug sector from 1995 to 2016.

Authors:  Marc-André Gagnon; Karena D Volesky
Journal:  Global Health       Date:  2017-08-22       Impact factor: 4.185

5.  Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.

Authors:  Olivier J Wouters; Panos G Kanavos; Martin McKEE
Journal:  Milbank Q       Date:  2017-09       Impact factor: 4.911

6.  Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.

Authors:  Ravi Gupta; Thomas J Bollyky; Matthew Cohen; Joseph S Ross; Aaron S Kesselheim
Journal:  BMJ       Date:  2018-03-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.